Diabetes Canada / CSEM Professional Conference

#DCAN2020

For new registrations, please allow one hour for your registration to become active in the platform.
AUGUST 2-3

October 28

NO TRAVEL NEEDED

NO TRAVEL NEEDED

GUEST EXPERTS

BREAKOUT SESSIONS

LEARN & NETWORK

LEARN & NETWORK

Why Attend?

Attend Canada’s most highly anticipated diabetes-related conference in the comfort of your own home and learn about significant advances in diabetes research, treatment, and care. Through the course of the conference, delegates will have the opportunity to attend original research presentations and take part in information sharing with leading diabetes, endocrinology, and related field experts. More information on programming to come! Grab your spot today.

2020 Diabetes Canada/CSEM Professional Conference Program At–A–Glance

For more information about the 2020 Diabetes Canada/CSEM Professional Conference, please visit dcanconference.ca

*Note: all times in ET. Schedule is tentative and may change as program is confirmed.
11:00 – 16:00

Diabetes Canada & Diabetes Action Canada Trainee Day

Theme: Shifting the Paradigm in Patient-Oriented Research: Are We There Yet?

Agenda
11:00 – 16:45

CSEM 14th Annual Endocrine Residents’ Day Review Course

Dr. Breay Paty

Faculty Representative
Dr. Nadia Moledina
Resident Representative
Agenda
10:45 – 11:45

Plenary Lecture 1: Diabetes and Mental Health: Never a Better Time to Expand Scope of Practice

Chair
Dr. Kerry Mansell
 
Dr. Michael Vallis
 

Michael Vallis

Dr. Vallis is a registered health psychologist based in Halifax, Canada. He is a Health Behaviour Change Consultant and Associate Professor in Family Medicine at Dalhousie University. His main area of expertise is adult health psychology, with an emphasis on obesity, diabetes, cardiovascular risk and gastroenterology. He spends most of his time training health-care providers in behaviour change for chronic disease management. He regularly supervises clinical and academic students at Dalhousie and is active in research on motivation, behavioural change and adaptation to chronic disease. He consults nationally, as well as internationally, and is heavily involved in academic publications, journal editing, and clinical practice guidelines (2020 and 2006 Canadian Clinical Practice Guidelines for the Management of Obesity and 2018, 2013, 2004 Diabetes Canada Clinical Practice Guidelines). He was recently awarded a Queen’s Diamond Jubilee Medal by the Government of Canada on the recommendation of Diabetes Canada (formerly the Canadian Diabetes Association).

Disclosures

I have a relationship with a for-profit and/or a not-for-profit organization to disclose
Consultant and speaker/trainer: Novo Nordisk; Sanofi, Abbvie, Lifescan, Merck

12:00 – 12:45

Session 1: Exercise in a COVID Era

Chair
Janice Knapp
 
Dr. Jane Yardley
 

Jane

Dr. Yardley completed her PhD in Population Health at the University of Ottawa in 2011. Her doctoral thesis focused on the effects of resistance exercise, on its own or combined with aerobic exercise, in physically active individuals with type 1 diabetes. She is now an Associate Professor at the University of Alberta, and part of the Physical Activity and Diabetes Laboratory at the Alberta Diabetes Institute. Dr. Yardley is still performing research related to type 1 diabetes and exercise. Her current projects focus on resistance exercise and high intensity intermittent intervals, with a particular interest in sex-related differences in blood glucose responses to these modalities. She is a co-author of the 2016 American Diabetes Association Position Statement on Diabetes and Exercise/Physical Activity and a recipient of the Heart and Stroke Foundation of Canada Alberta New Investigator Award.

Disclosures

I have a relationship with a for-profit and/or a not-for-profit organization to disclose
Speaker's fees: Dexcom Canada
In-kind research support: OneTouch Canada, Abbott Nutrition Canada, Dexcom Canada

Dr. Ronald Sigal
 

Ronald

Dr. Sigal is Professor of Medicine, Kinesiology, Cardiac Sciences and Community Health Sciences at the Cumming School of Medicine, University of Calgary. He is active in clinical medicine, teaching and research.
Dr. Sigal completed residencies in Internal Medicine and Endocrinology at McGill University, and a research fellowship at the McGill Nutrition and Food Sciences Centre. He then completed a Master of Public Health degree and a research fellowship in Epidemiology and Genetics at Harvard University. He has held a Health Senior Scholar award from Alberta Innovates-Health Solutions, and previously a Canadian Institutes of Health Research (CIHR) New Investigator Award. Dr. Sigal’s research focuses on clinical trials related to physical activity, diabetes, kidney disease and cardiovascular disease.
Dr. Sigal has been the lead author of the guidelines on Physical Activity/Exercise for Diabetes Canada (2003, 2008, 2013, 2018) and the American Diabetes Association (2006), and co-Chair of the writing group for the American Diabetes Association Position Statements on Physical Activity/Exercise and Diabetes in 2010 and 2016. He contributed to the chapters on Chronic Diseases and Cardiometabolic Health for the 2018 Physical Activity Guidelines for Americans

Disclosures

I have a relationship with a for-profit and/or a not-for-profit organization to disclose
Honoraria for advisory board meeting: Novo Nordisk
Local PI for multicentre trials: Novo Nordisk, Sanofi

Session 2: Telehealth and Virtual care

Chair
TBC
 
Dr. Jeff Winterstein
 

Jeff Winterstein

Bio---TBA

Disclosures

I have a relationship with a for-profit and/or a not-for-profit organization to disclose
Speaker: ABBOTT, AZ, MERCK, JANSSEN, BI/LILY, SANOFI, BAUSCH, NOVO NORDISK
Grants: NovoNordisk, Astra Fenica

Session 3: TBD (Traditional/Originals Food Guide Presentation Cancelled)

Chair
TBD
 
TBD
 
13:00 – 13:45

Lunch/Networking/Exhibits/Poster Hall
Co–Developed Accredited Lunch – Under the Umbrella: Using Knowledge and Preparation to Safeguard Against Severe Hypoglycemia

Dr. Jean- François Yale
 

Dr. Jean-François Yale

Bio--- TBA

Disclosures

SPEAKERS BUREAU/HONORARIA: AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Janssen, Medtronic, Merck, NovoNordisk, Sanofi, Takeda
CONSULTING FEES: AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Janssen, Medtronic, Merck, Mylan, NovoNordisk, Sanofi

Lori Berard
 

Lori Berard

Bio--- TBA

Disclosures

SPEAKERS BUREAU/HONORARIA: AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Janssen, Medtronic, Merck, NovoNordisk, Sanofi, Takeda
CONSULTING FEES: AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Janssen, Medtronic, Merck, Mylan, NovoNordisk, Sanofi

14:00 – 14:50

Session 4: DIY Looping

Chair
Dr. Kerry Mansell
 
Kate Farnsworth
 

Kate

Kate has been heavily involved in the Do-It-Yourself #wearenotwaiting movement since her daughter Sydney was diagnosed with type 1 diabetes at the age of 8. With a background in information technology and graphic design, Kate has lent her skillset to developing diabetes watch faces for remote monitoring used by patients worldwide. Kate has created an online patient-driven support community for people who are exploring DIY closed-loop solutions and continues to advocate for all people with diabetes to have access to the best tools to manage their diabetes.

Disclosures

I have a relationship with a for-profit and/or a not-for-profit organization to disclose

Allied Health Oral Abstract Session 1

Chair
Dr. JM Gamble

  1. Speaker: Diana Sherifali, The effect of diabetes health coaching on glycemic control and quality of life in adults living with type 2 diabetes: a community-based randomized controlled trial.
  2. Speaker: Akshay Jain, Outcomes with Intermittently Scanned Continuous Glucose Monitoring (isCGM) Used Prior to First Appointment with an Endocrinologist, Compared to Fingerstick Monitoring (FSBGM): SPOT-FIRST study
  3. Speaker: Selina L. Liu, Patient and Paramedic Experiences with a Direct Electronic Referral Program for Hypoglycemia Education Following Paramedic Service Assist-Requiring Hypoglycemia: A Qualitative Study
  4. Speaker: Sonja M. Recihert, Benefits of Flash Glucose Sensors on Type 2 Diabetes Management and Exercise Behaviour in Insulin and Non-Insulin treated Patients

Allied Health Oral Abstract Session 2

Chair
Susie Jin
 
  1. Speaker: Heather A. Hinz, The Association of Exercise Blood Glucose on Post-Exercise Hypoglycemia in Type 1 Diabetes
  2. Speaker: Harleen Ghuttora, Variation in Patient-described Barriers and Facilitators to Diabetes Self-Management by Glycemic Control and Individual-Level Characteristics
  3. Speaker: Jana L. Slaght, Evaluation of a novel approach to health care delivery: The inclusion of an Indigenous Knowledge Keeper and Art therapy in a youth onset type 2 diabetes clinic
  4. Speaker: Elizabeth A. Cummings, Barriers and facilitators to providing psychosocial care in pediatric diabetes in our province
15:00 – 15:45

Session 5: Drugs in pregnancy (metformin use / MiTY Trial)

Chair
Julia Bannister
 
Dr. Denice Feig
 

Denice

Dr. Feig is a Professor of Medicine in the Division of Endocrinology and Metabolism at the University of Toronto, and holds a cross-appointment in both the Department of Obstetrics and Gynecology and the Department of Health Policy, Management and Evaluation. She is a Senior Clinician Scientist at the Lunenfeld-Tanenbaum Research Institute, and an Adjunct Scientist at the Institute for Clinical and Evaluative Sciences. She is Head of the Diabetes and Endocrine in Pregnancy Program at Mount Sinai Hospital, Chair of the University of Toronto Diabetes in Pregnancy Study Group and Past Chair of the Diabetes in Pregnancy Interest Group for the American Diabetes Association. Her research focus is in the area of diabetes in pregnancy and she was awarded the Canadian Diabetes in Pregnancy Study Group Award for Excellence.

Disclosures

I have a relationship with a for-profit and/or a not-for-profit organization to disclose

Session 6: Update on Diabetes Canada Clinical Practice Guidelines

Chair
Dr. Harpreet Bajaj
 

Harpreet

Dr. Bajaj is an Endocrinologist and Director of late-phase research at LMC Healthcare. Dr Bajaj started his Endocrinology practice with LMC Brampton in 2009, after completing his clinical fellowship at the Cleveland Clinic (Ohio, USA). Dr Bajaj’s medical education was at Maulana Azad Medical College (New Delhi, India), following which he attained a Masters of Public Health (Epidemiology) at State University of New York in Albany (New York, USA).
Dr. Bajaj is a Research Associate at Mount Sinai Hospital, Toronto, and an adjunct lecturer at McMaster University. He is the principal investigator for the Canadian Diabetes Prevention Program (CDPP), a virtual one-year health and wellness coaching program funded by the Public Health Agency of Canada.
He volunteers with numerous community public health organizations, as well as media programs, with the intent of raising public awareness on diabetes prevention and treatment, with a specific focus on the South Asian origin population in Canada. He is the founder of STOP Diabetes Foundation, a registered charitable organization working to reduce the burden of diabetes in Peel region of Ontario. Dr. Bajaj serves Diabetes Canada on the Executive Board of the Professional Section Executive and as the Vice Chair of clinical practice guidelines.

Disclosures

I have a relationship with a for-profit and/or a not-for-profit organization to disclose
Honorariums: Banting & Best Diabetes Centre, Brain and Cognition Discovery Found., Diabetes Canada, Eli Lilly, Hu.
Piad to LMC (Institution): Amgen, AstraZeneca, Boehringer Ingelheim, Ceapro, Eli Lilly, Gilead, Janssen, Kowa, Madrigal, Merck

Dr. Peter Senior
 

Katie Pundyk

Dr. Senior is Professor of Medicine at the University of Alberta. His research activities and clinical practice are focused on the management and prevention of type 1 diabetes and its complications, and beta cell replacement therapies, including islet transplantation.
He serves as the Chair of the Clinical Practice Guidelines Steering Committee and is a member of the Diabetes Canada Board of Directors.

Disclosures

I have a relationship with a for-profit and/or a not-for-profit organization to disclose
Honorarium for CGP chair role: Diabetes Canada
Grant funding to my institution for participation as local PI in clinical trials: Novo Nordisk, Viacyte, JDRF

Dr. Lorraine Lipscombe
 

Lorraine

Dr. Lipscombe is the Director of the Division of Endocrinology at Women’s College Hospital and an Associate Professor of Medicine at University of Toronto. She completed her MD from McGill University in 1998, followed by Internal Medicine and Endocrinology training and an MSc in Clinical Epidemiology from University of Toronto. Dr. Lipscombe is a Clinician Scientist with a research focus on the epidemiology, care and prevention of diabetes, and she holds a Diabetes Investigator Award from Diabetes Canada.

Disclosures

I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose

Session 7: Chemotherapy and corticosteroid use. Can we do better to manage our patients living with diabetes?

Chair
Cynthia Keith
 
Dr. Hélène Long
 

Hélène

Dr. Long studied Medicine and did her residence training in Internal Medicine and Endocrinology at the University of Montreal. She works at the CISSS Laval and at the Laval Regional Diabetes Center as a Clinical Endocrinologist and Medical Coordinator. She was also an associated member at the Montreal University Hospital Center from 2006 to 2011. Her particular interests are teaching (patients, trainees and family doctors) and the endocrinology of pregnancy.

Disclosures

I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose

Steve Chalifoux
 
16:00 – 16:45

Isabel Lockerbie Address: Understanding siwinikan aspinewin ("Diabetes") and the whole human

Chair
Dr. Kerry Mansell
 
Dr. James Makokis
 

James

Dr. Makokis is from the Saddle Lake Cree Nation in Northern Alberta. He holds a Bachelor of Science in Nutrition and Food Sciences ('04), a Master of Health Science in Community Nutrition from the University of Toronto ('06) and a Doctorate in Medicine from the University of Ottawa ('10). He received certification from the Aboriginal Family Medicine Training Program at the University of British Columbia ('12). Currently, he works as the sole Family Physician at Kehewin Health Services on Kehewin Cree Nation. Dr. Makokis leads one of North America’s most progressive and successful transgender focused medical practices in south Edmonton, and has been featured on the CBC, AJ+, and the Thompson Reuters Foundation for his work in this area.
His strong connections to his cultural beliefs, nehiyaw maskihkiya, preventative health through the Cree medical system, spirituality, and Two-spirit perspective has helped him save lives within the LGBTQ2 and First Nation communities. Dr. Makokis participated alongside his husband as ""Team Ahkameyimok"" on Season 7 of The Amazing Race Canada and won. Dr. Makokis currently serves on the Board of the Waakebiness-Bryce Institute of Indigenous Health at the University of Toronto and Indigenous Advisory Council at McEwan University, and is the former Board Chair of the inaugural Indigenous Wisdom Council of Alberta Health Services. He has previously served on the boards of the Indigenous Physicians Association of Canada, Indspire and the Two Spirit Circle.

Disclosures

I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose

17:30 – 18:15

Networking/Exhibits

Networking/Exhibits/Poster Hall
Co–Developed Accredited Symposium– Take Charge of CKD in T2DM

Dr. Alice Cheng
 

Alice

Dr. Cheng is a member of the Division of Endocrinology and Metabolism at Credit Valley Hospital in Mississauga and St. Michael's Hospital in Toronto and is an Associate Professor in the Department of Medicine at the University of Toronto. She completed medical school, internal medicine and Endocrinology training at the University of Toronto and has completed the Master Teacher Program offered through the Department of Medicine. She has served on the Expert Committee for the 2003 Diabetes Canada clinical practice guidelines, the Steering and Expert Committees for the 2008 revision and served as Chair of the 2013 Diabetes Canada clinical practice guidelines. She is currently the Chair of the Professional Section of Diabetes Canada and an Associate Editor for the Canadian Journal of Diabetes. She is Past-Chair of the Guidelines Committee for the Canadian Society of Endocrinology and Metabolism. She has received a Certificate of Recognition from the Ontario College of Family Physicians, the national Charles H. Best Award and the Gerald S. Wong Service Award from Diabetes Canada in recognition of her contributions.

Disclosures

Speaking honoraria: Brandaide, Liv Agency, Meducomm, EOCI, Antibody Communications, Bridge Communications, Sea Courses, Sutherland Global Services Canada ULC, Abbott, Astra Zeneca, Bausch, Boehringer Ingelheim, Eli Lilly, Janssen, HLS Therapeutics, Medtronic, Merck, Novo Nordisk, Sanofi
Advisory board member: Abbott, Astra Zeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Janssen, Medtronic, Merck, Medtronic, Novartis, Novo Nordisk, Sanofi, HLS Therapeutics
Clinical trial investigator / steering committee member: Eli Lilly, Boehringer Ingelheim, Sanofi, Applied Therapeutics

Dr Louis-Philippe Girard
 

Dr. Louis-Philippe Girard

Dr. Louis Girard joined the Division of Nephrology at the University of Calgary in July of 2010. He is a Nephrologist and Clinical Associate Professor. Within the Division of Nephrology, Dr. Girard focuses on clinical immunology and infectious diseases in chronic kidney disease patients. He is the medical director of the Glomerulonephritis Clinic and the Medical Director of Apheresis. Furthermore, he has developed a multi-disciplinary rare diseases clinic that operates out of the Southern Alberta Renal Program. In addition to patients with GN/Vasculitis, this clinic focuses on patients with complement dysregulation, Tuberous Sclerosis and ADPKD. Dr. Girard has a strong clinical research interest. He is currently the local primary investigator on numerous global trials in glomerulonephritis and vasculitis. Dr. Girard has a strong commitment to education and has won numerous awards for his teaching contributions at all levels of medical training.

Disclosures

Honoraria for CME and educational slide development: Alexion, Bayer, BI-Lilly, Astra Zeneca, Janssen, Merck, Otsuka, Bausch Health Funded grants or clinical trials: Otsuka
Member: CDP Network

10:45 – 11:45

Plenary Lecture 2: COVID-19 and Diabetes

Chair
Dr. Christine Doucette 
 
Dr. Alice Cheng
 

Alice

Dr. Cheng is a member of the Division of Endocrinology and Metabolism at Credit Valley Hospital in Mississauga and St. Michael's Hospital in Toronto and is an Associate Professor in the Department of Medicine at the University of Toronto. She completed medical school, Internal Medicine and Endocrinology training at the University of Toronto and has completed the Master Teacher Program offered through the Department of Medicine. She has served on the Expert Committee for the 2003 Diabetes Canada clinical practice guidelines, the Steering and Expert Committees for the 2008 revision and served as Chair of the 2013 Diabetes Canada clinical practice guidelines. She is currently the Chair of the Professional Section of Diabetes Canada and an Associate Editor for the Canadian Journal of Diabetes. She is Past-Chair of the Guidelines Committee for the Canadian Society of Endocrinology and Metabolism. She has received a Certificate of Recognition from the Ontario College of Family Physicians, the national Charles H. Best Award and the Gerald S. Wong Service Award from Diabetes Canada in recognition of her contributions.

Disclosures

I have a relationship with a for-profit and/or a not-for-profit organization to disclose
Abbott, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novartis, Novo Nordisk, Bayer, Sanofi, HLS Terapeutics, Eisa

12:00 – 12:45

Session 8: Clinical Stream: Lifestyle and T2D Prevention

Chair
Dr. Jane Yardley
 

Jane

Dr. Yardley completed her PhD in Population Health at the University of Ottawa in 2011. Her doctoral thesis focused on the effects of resistance exercise, on its own or combined with aerobic exercise, in physically active individuals with type 1 diabetes. She is now an Associate Professor at the University of Alberta, and part of the Physical Activity and Diabetes Laboratory at the Alberta Diabetes Institute. Dr. Yardley is still performing research related to type 1 diabetes and exercise. Her current projects focus on resistance exercise and high intensity intermittent intervals, with a particular interest in sex-related differences in blood glucose responses to these modalities. She is a co-author of the 2016 American Diabetes Association Position Statement on Diabetes and Exercise/Physical Activity and a recipient of the Heart and Stroke Foundation of Canada Alberta New Investigator Award.

Disclosures

I have a relationship with a for-profit and/or a not-for-profit organization to disclose
Speaker's fees: Dexcom Canada
In-kind research support: OneTouch Canada, Abbott Nutrition Canada, Dexcom Canada

Dr. Harpreet Bajaj
 
Dr. Jon McGavock
 

Dr. Jon McGavock

Dr. McGavock is an Associate Professor in the Department of Pediatrics and Child Health within the Faculty of Health Sciences at the University of Manitoba. He is currently the co-leader of the DREAM Theme at the Children's Hospital Research Institute of Manitoba. Dr. McGavock held a CIHR New Investigator Salary Award from 2010-2014 and, from 2014-2019, held a CIHR Applied Health Chair in Obesity and Resilience in Indigenous Youth. He is currently one of 12 PIs for the Diabetes Action Canada SPOR Network and the PI for a CIHR Pathways Component 3 team grant focused on prevention of type 2 diabetes among Indigenous youth.

Session 9: Pre-clinical Stream: Islet Dysfunction

Chair
Dr. Rob Screaton
 
Dr. Patrick MacDonald
 

Patrick

Dr. MacDonald completed his PhD in Toronto and followed this with postdoctoral research in Lund, Sweden, and in Oxford. Since 2006, he has run a laboratory at the University of Alberta in Edmonton that has focused on understanding cells in the pancreas that make insulin and other hormones.

Disclosures

I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose

Dr. Barbara Corkey
 

Barbara

Dr. Corkey has been the Zoltan Kohn Professor of Medicine and Vice Chair for Research in the Department of Medicine at Boston University. Dr. Corkey has been a leader in the fields of diabetes and obesity research for over 50 years, with about 200 related publications and 40 years of continuous government research support. The Corkey laboratory is engaged in research on obesity and diabetes, with a particular focus on metabolic signal transduction in ß-cells, adipocytes and hepatocytes, intercellular communication via circulating redox and the role of hyperinsulinemia in obesity and diabetes. Projects in metabolic regulation have been ongoing since 1981 using such techniques as single cell imaging, metabolic profiling, ionic fluxes and membrane potential, respiration, redox state, reactive oxygen species generation and diet-induced obesity and diabetes models. She does seminal work on the molecular basis of nutrient signaling that has a major impact on our current understanding of health and disease. Finally, Barbara has received numerous honors, including the NIH MERIT Award, National Honorary Membership in Iota Sigma Pi, the National Honor Society of Women in Chemistry, Women in Science Lecturer at the Boston Museum of Science, the George Bray Founders Award of the Obesity Society, the Charles H. Best Lectureship and Award, University of Toronto, and the Banting Medal for Scientific Achievement from the American Diabetes Association.

Disclosures

I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose

Session 10: Translational Stream: Early Life Determinants of Diabetes Risk and Pathogenesis

Chair
Dr. Vern Dolinsky
 
Dr. Brandy Wickow

Brandy Wickow

Dr. Wicklow is a pediatric endocrinologist, Associate Professor in Pediatrics and Child Health at the University of Manitoba, and Clinician Scientist at the Children's Hospital Research Institute of Manitoba. Her research focuses on the determinants of childhood onset type 2 diabetes and renal complications. She is a principle investigator on 2 cohort studies; the next generation study, which examines the intergenerational risk of type 2 diabetes, and the iCARE cohort study (co-led by Dr Allison Dart), which is examining the psychological and sociological risks for the development of early renal disease in youth with type 2 diabetes. She works closely in partnership with Indigenous communities, families and patients to conduct relevant, patient-oriented research aimed to reduce health disparity and its impacts on First Nations families as it relates to type 2 diabetes.

Disclosures

I have a relationship with a for-profit and/or a not-for-profit organization to disclose

Dr. Jenny Bruin

Jenny

Dr. Bruin has been an Assistant Professor at Carleton University in the Department of Biology and Institute of Biochemistry since September 2016. Her lab studies the pathogenesis of diabetes with a focus on islet biology, pancreas development and toxicology. In particular, she is investigating how exposure to persistent environmental pollutants, either during fetal development or adulthood, influences diabetes incidence. Dr. Bruin’s lab is funded by CIHR, NSERC and the Ontario Institute of Regenerative Medicine.

Disclosures

I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose

13:00 – 13:45

Lunch/Networking/Exhibits/Poster Hall

14:00 – 14:50

Clinical Stream Oral Abstract Session 1

Chair
Dr. James Kim
 
  1. Speaker: Emilie Palisaitis, A Meal Detection Algorithm for the Artificial Pancreas: A Randomized Controlled Clinical Trial in Adolescents with Type 1 Diabetes
  2. Speaker: Milena Cioana, Hypertension and Albuminuria in Pediatric Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
  3. Speaker: Dorsa Majdpour,Novel Fully-Automated Fiasp-plus-Pramlintide Artificial Pancreas for Type 1 Diabetes: Randomized Controlled Trial
  4. Speaker: Allison Dart, Urine cytokine levels and albuminuria progression over 2 years in youth with Type 2 Diabetes

Pre-clinical Oral Abstract Session 2

Chair
Dr. Robin Duncan
 
  1. Speaker: Nivedita Seshadri, Investigating the molecular and metabolic regulators of rhythmic insulin secretion over 24 hours
  2. Speaker: Yuanjie Zou, Lysosomal dysfunction and impaired autophagy exacerbate hypoxia-induced β-cell death and islet graft failure
  3. Speaker: Scott A. Campbell, RGS9 is Required for Glucose-induced Beta-cell Proliferation in Ex Vivo Pancreatic Islets
  4. Speaker: Evgeniy Panzhinskiy, CRISPR-Cas9 optogenetic system for insulin expression in human embryonic stem cell-derived beta-like cells

Translational Oral Abstract Session 3

Chair
Dr. Pedro Geraldes
 
  1. Speaker: Hongyan Liu, Empagliflozin is Associated with Increased Plasma Lipid Metabolites in Type 1 Diabetes
  2. Speaker: Evgenia Fadzeyeva, Regulation of Glucose Metabolism via the Intra-Islet DPP4/Incretin Axis
  3. Speaker: Peter Overby, Effects of Carbamazipne and other Nav 1.7 inhibition on Human Pancreatic β-cell survival and type 1 diabetes initiation
  4. Speaker: Taylor S. Morriseau, Investigating the Contribution of the HNF-1αG319S Gene Variant to Early-Onset Type 2 Diabetes (T2D) using MIN6 β-cells and Mice
15:00 – 15:45

Session 11: Clinical Stream: T2D Pharmacotherapy: SGLT2 inhibitors and GLP-1 receptor agonists in combination

Chair
Dr. Eyal Kraut
 
Dr. Jeremy Gilbert
 

Jeremy

Dr. Gilbert completed his medical degree, Internal Medicine training and Endocrinology residency at the University of Toronto. He is an associate professor at the University of Toronto. He is the Program Director for adult endocrinology and metabolism at the University of Toronto. He has authored a chapter in the 2013 and 2018 Diabetes Canada clinical practice guidelines and was a member of the Steering Committee of the 2018 Diabetes Canada guidelines. He is on the Executive and is a National Editor for the Canadian Journal of Diabetes. He is a passionate teacher and his academic interest is in undergraduate, postgraduate and continuing medical education in diabetes and endocrinology. He has received numerous awards for outstanding teaching.

Disclosures

I have a relationship with a for-profit and/or a not-for-profit organization to disclose

Dr. Ron Goldenberg
 

Session 12: Pre-clinical Stream: T1D Biomarkers and Disease Prediction

Chair
Dr. Bruce Verchere
 
Dr. Emily Sims
 

Emily Sims

Dr. Sims is a Physician Scientist specializing in pediatric endocrinology, with a long-term goal of addressing clinically relevant problems in diabetes utilizing molecular discovery. Her research focus revolves around the investigation of molecular mechanisms contributing to β-cell dysfunction and the development of diabetes, as well as the identification and verification of circulating biomarkers of β-cell dysfunction.

Disclosures

I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose

Dr. Megan Levings
 

Megan

Dr. Levings is a Professor in the Department of Surgery and School of Biomedical Engineering at the University of British Columbia. Her lab studies the biology and clinical application of a special kind of white blood cell, known as a T regulatory cell, that can be used as cellular therapy to stop harmful immune responses. She is internationally recognized in the field of human immunology and currently chairs the Federation of Clinical Immunology Societies Centers' of Excellence and is a member of the NIH-funded Immune Tolerance Network Steering Committee.

Disclosures

I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose

Session 13: Translational Stream: Developmental Origins of Diabetes

Chair
Dr. Jon McGavock
 
Dr. Treena Delormier
 

Treena

Dr. Treena Wasonti:io Delormier is Kanien’kehá:ka (Mohawk). She is an Associate Professor in the School of Human Nutrition at McGill University, and Associate Director of the Centre for Indigenous Peoples Nutrition and Environment. She is the Scientific Director of the Kahnawake Schools Diabetes Prevention Project (KSDPP), a 24-year community-university partnership and health promotion program in her home community of Kahnawake, near Montreal, Quebec. Dr. Delormier’s research interests include Indigenous research methodologies, qualitative methodologies, Indigenous Peoples’ food systems and the prevention of diabetes and obesity prevention through community mobilization strategies.

Disclosures

I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose

Linda Diffey
 

Linda

Dr. Diffey is a member of the Peepeekisis Cree Nation in the Treaty 4 region and Indigenous Scholar in Community Health Sciences and Ongomiizwin Indigenous Institute of Health and Healing. She co-led the development and implementation of the Indigenous Health curriculum in undergraduate medical education at the Max Rady College of Medicine and served as a co-editor of the national undergraduate medicine curricular framework for Indigenous health that was developed by the Indigenous Physicians Association of Canada and the Association of Faculties of Medicine of Canada.
Linda is a PhD candidate in the Applied Health Sciences Program at the University of Manitoba. Her dissertation work focuses on the experiences of physician instructors during the implementation of anti-colonial, anti-racist pedagogy in medical education. Other areas of interest include examining systemic colonial oppression within health-related institutions and the application of Indigenous resurgence as a theoretical foundation within Indigenous research methodology.
She has been actively engaged in the mentorship and support of Indigenous students in health research and education for over ten years, and is co-Principal Investigator of the Prairie Indigenous Knowledge Exchange Network (PIKE-Net), part of the CIHR Indigenous Mentorship Network program. In 2018, she was awarded an Indigenous Award of Excellence in the Community Builder category in recognition of her work that seeks to create a safe and supportive work and learning environment for Indigenous students, faculty and staff at the University of Manitoba.

Disclosures

I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose

16:00 – 16:45

Session 14: Clinical Stream: Pediatric to Adult Diabetes Care Transition

Chair
Dr. Claudia Gagnon
 
Dr. Sonia Butalia

Sonia

Dr. Butalia is a Clinician Scientist in the Departments of Medicine and Community Health Sciences at the University of Calgary. Her research interests are in innovative tools and strategies to improve diabetes and other cardiovascular risk factors in the community. Her program of work importantly engages and is informed by people (i.e. patient partners), health-care providers and decision makers. Her research program is supported by CIHR, Diabetes Canada, the Heart and Stroke Foundation of Canada and Alberta Health Services. Dr. Butalia is also a co-author of several national guidelines in diabetes and hypertension and has contributed to several textbooks. She also teaches at the University of Calgary’s medical school, supervises trainees, and was awarded a Gold Star Resident Teaching Award for her contributions. Finally, she has recently become the Scientific Director of the Diabetes, Obesity and Nutrition Strategic Clinical Network for the province of Alberta.

Disclosures

I have a relationship with a for-profit and/or a not-for-profit organization to disclose
Funded, peer-reviewed grants from not-for profit organizations: Diabetes Canada, Heart and Stroke Foundation of Canada, Alberta Health Services

Dr. Katie Pundyk
 

Katie Pundyk

Katie Pundyk is a Pediatric Endocrinologist at the Winnipeg Children's Hospital, and an Assistant Professor at the University of Manitoba. She completed her Pediatrics residency at the University of Manitoba, and her clinical Pediatric Endocrinology fellowship at the University of Ottawa. She completed an additional year of research training at the University of Manitoba focusing on transition of care in youth with type 2 diabetes, with funding from the Children's Hospital Research Institute of Manitoba and Manitoba Medical Service Foundation.

Disclosures

I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose

Session 15: Pre-clinical Stream: Adipose Tissue Dysfunction, Obesity and Diabetes

Chair
Dr. Erin Mulvihill
 
Dr. Gareth Lim
 

Gareth

Dr. Lim is an Assistant Professor in the Department of Medicine at the University of Montréal and a Principal Scientist at the University of Montreal Hospital Research Centre (CRCHUM). Currently, he holds the Canada Research Chair in Adipocyte Development. His research is focused on understanding the metabolic functions of the scaffold protein in fat cells and pancreatic beta-cells, and his lab is currently supported by CIHR and NSERC.

Disclosures

I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose

Dr. Mathieu Laplante
 

Mathieu

During my graduate studies (MSc/PhD, Université Laval, 2002-2007), I developed an expertise in physiology and endocrinology, focusing my attention on adipose tissue metabolism in response to PPARg agonists. In order to improve my capacity to further characterize and understand the molecular mechanisms controlling cellular metabolism, I joined the laboratory of David M. Sabatini (Massachusetts Institute of Technology (MIT)), a world expert in cell signaling primarily known for its work with the kinase mTOR. Over the years that followed (2007-2011), I have been involved in many projects aimed at characterizing the role of mTOR in health, diseases and aging. Over these years, I have published several original articles and reviews on the mTOR pathway. During my postdoctoral training, I learned and mastered several state-of-the-art techniques in molecular biology. I also got the chance to learn how to generate transgenic mouse models. This unique expertise in physiology and molecular biology has greatly helped the establishment of my own laboratory in 2011 (Université Laval). Today, I lead a group of young scientists whose primary objective is to improve the understanding of the molecular mechanisms controlling metabolism in response to environmental challenges. We have a special interest in identifying new biological processes controlling the early development of white adipocytes.

Disclosures

I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose

Session 16: Translational Stream: Using Nutrition to Achieve T2D Remission and Metabolic Health

Chair
Dr. Jim Johnson
 
Dr. Jon Little
 

Jonathan

Dr. Little is an Associate Professor in the School of Health and Exercise Sciences at the University of British Columbia in Kelowna, BC, Canada. He is a Canadian Institutes of Health Research (CIHR) New Investigator and Michael Smith Foundation for Health Research (MSFHR) Scholar whose research focuses on optimizing diet and exercise interventions for the prevention and treatment of type 2 diabetes. He has published over 115 peer-reviewed journal articles in the areas of exercise metabolism, nutrition, type 2 diabetes, obesity and immunology. Ongoing nutrition studies in his lab are exploring how low-carbohydrate diets, nutritional ketosis, and exercise impact glucose control, cardiovascular risk and inflammation.

Dr. Satchin Panda
 

Dr. Satchin Panda

Dr. Panda is a Professor at the Salk Institute, La Jolla, California. His research focuses on circadian coordination of behavior, physiology and metabolism. His discovery of how a blue light sensor in the eyes affects sleep-wake cycle, depression and alertness is leading a new revolution in managing light to improve health. Recently, Dr. Panda discovered that maintaining a daily feeding-fasting cycle – popularly known as Time-restricted eating (TRE) – can prevent and reverse many chronic diseases and increase lifespan. His lab uses Drosophila, rodents and primates for a mechanistic understanding of the role of circadian rhythm in health. His lab has developed a smartphone app “myCircadianClock,” to facilitate translation of his research to human patients.

Disclosures

I have a relationship with a for-profit and/or a not-for-profit organization to disclose

17:00 – 17:45

Networking/Exhibits/Poster Hall

Co–Developed Accredited Symposium – Latest Updates on COVID-19 and Virtual Care: What You Need to Know— From Vaccines to Masks to Optimizing Virtual Clinics

Dr. Peter J. Lin

Peter J. Lin

Dr. Peter Lin is the Director of Primary Care Initiatives at the Canadian Heart Research Centre. He has a busy family practice in Toronto, Canada. He is also a contributing author to the Canadian Diabetes Guidelines 2013 and 2018 on the vascular protection section. He is also Associate Editor for the Elsevier WebPortal - PracticeUpdate Primary Care. Dr. Lin is also the health columnist for CBC and has been actively tracking the COVID-19 Pandemic since the beginning.

Dr. Ilana J Halperin

Dr. Ilana J Halperin

Dr. Ilana Halperin is a staff endocrinologist at Sunnybrook and assistant professor of Medicine at The University of Ontario. She is the Quality and Innovation lead for the Division of Endocrinology and Medical Director of the Diabetes in Pregnancy Program at Sunnybrook. She was an early adopter of virtual care and has an expertise in leveraging technology to optimize care.

Disclosures

Speakers Fees: Sanofi, Novonordisk, Boehringer Ingelheim, Dexcom Canada, Abbott Diabetes Care
Advisory Boards: Sanofi, Novonordisk, Dexcom Canada, Abbott Diabetes Care
Site for clinical trials: Novonordisk

10:45 – 11:45

Dr. Jacques Genest Lecture: New Developments in Imaging for Endocrinologists

Chairs
Dr. Stan Van Uuum, Dr. Sana Ghaznavi
 
Prof. Dr. James Nagarajah
 

James Nagarajah

Dr. Nagarajah is a professor for Nuclear Medicine currently appointed in September 2016 as Assistant Professor in Radboud University Medical Center in Nijmegen, The Netherlands. He started his medical training in July 2004 in the department of Nuclear Medicine in Wuppertal, Germany and moved to University Hospital in Essen, Germany to accomplish his training. Here, he was appointed as an attending physician and the head of the PET centre from November 2011 on. From July 2013, he was appointed as a Visiting Investigator in Memorial Sloan Kettering Cancer Center, New York, USA, where he became a Visiting Professor in July 2015. Here, he worked with Professors Wolfgang Weber and James Fagin focusing on re-differentiation approaches in radio-iodine refractory thyroid cancer. He is a PI in many ongoing prospective investigator-initiated clinical studies for advanced thyroid cancer and prostate cancer using different radio-ligands for theranostics.

Disclosures

I have a relationship with a for-profit and/or a not-for-profit organization to disclose
Teaching: Genzyme and Sanofi
Clinical Studies: ABX, Ger

12:00 – 12:45

Dr. Henry Friesen Lecture: Genetic testing in daily clinical endocrinology practice with a focus on diabetes

Chairs
Dr. Stan Van Uum, Dr. Mahua Ghosh
 
Dr. Andrew Hattersley

Andrew

"Dr. Hattersley is the Professor of Molecular Medicine at the University of Exeter, UK and a practicing consultant Diabetologist at the Royal Devon and Exeter hospital. He trained in Medicine at the Universities of Cambridge and Oxford. His postgraduate education was in London, Oxford and Birmingham. Since he moved to Exeter in 1995, he has published over 600 papers, given more than 300 national and international lectures and received many national and international awards for his research, including being appointed as a Fellow of The Royal Society in 2010 and being awarded a CBE in 2017.
Dr. Hattersley is a Clinician Scientist who has made outstanding scientific discoveries in diabetes that have transformed our understanding, diagnosis and treatment of genetic forms of diabetes.
In 1995, he and Sian Ellard established a genetic laboratory in Exeter that is now world leading for monogenic diabetes diagnosis and research; receiving over 20,000 samples from 104 countries. They have described alone, or with others, 24 new genetic causes of diabetes; over half of all genetic subtypes.
Dr. Hattersley has led the studies which have carefully characterized the diabetes and other clinical features of these patients. These findings have been central in improving diagnosis, management and treatment for patients with monogenic diabetes throughout the world. Dr. Hattersley’s major advance has been to take beta-cell science into treatment of patients. After proving mutations in the beta-cell potassium channel were the most common cause of neonatal diabetes, he went on to show that these patients could replace their insulin injections with sulphonylurea tablets and improve blood glucose control. He ensured patients benefitted by offering free genetic testing for every patient with diabetes in the world diagnosed before 6 months.
He continues to identify new and important genes for beta-cell development, function and destruction by studying neonatal diabetes patients. Gene discovery in patients with a complete failure of pancreas development has shown that early human beta-cell development differs markedly from mice; this is critical information for creating human beta-cell replacement therapy from stem cells. For Dr. Hattersley, the patient is always the focus of his science.

13:00 – 13:45

Lunch/Networking/Exhibits/Poster Hall

Co–Developed Accredited Lunch – Teaming with Knowledge: Insights on Diabetes Team Collaboration and Initiating an Oral GLP-1 RA

Dr. Sara Stafford
 

Sara Stafford

Clinical Assistant Professor, University of British Columbia, BC

Disclosures

Grants/Research Support: AstraZeneca, CHRC, Novo Nordisk, Sanofi
Speakers Bureau/Honoraria: Abbott, AstraZeneca, Boehringer Ingelheim, CCRN, CPD network, Dexcom, Janssen, Lilly, MD Briefcase, Medtronic, Merck, Novo Nordisk, Sanofi
Consulting Fees: Abbott, AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk

Dr. Jane Ballantine

Jane Ballantine

Clinical Associate Professor, Department of Family Medicine, Cumming School of Medicine, University of Calgary, Alberta

Disclosures

Advisory Boards: Abbott, Aralez, AstraZeneca, Janssen, Novo Nordisk
Speaker: AstraZeneca, GSK, Lilly, Merck, Novo Nordisk,
Education: Alberta Innovates, Novo Nordisk, University of Calgary Adjudicator: Diabetes Canada
Representative Forum Delegate: Alberta Medical Association

Robert Roscoe

Robert Roscoe

Collaborative Community Pharmacist, Consultant, Rothesay, NB

Disclosures

Grants/Research Support: Boehringer Ingelheim, MontMed Canada, New Brunswick Health Research Foundation Speakers Bureau/Honoraria: Abbott Diabetes Care Canada, Allied Pharmacists Inc., AstraZeneca Canada, Bausch Health (Valeant [Bio-Vail] Pharmaceuticals), Bayer Healthcare, Becton Dickinson Canada, Boehringer-Ingelheim Canada, Canadian Pharmacists Association, Diabetes Canada, HLS Therapeutics, Janssen Canada, Lilly Canada, MDBriefcase, MontMed Canada, Novo Nordisk, Roche Diagnostics, RxBriefcase, Sanofi Canada
Consulting Fees: Abbott Diabetes Care, AstraZeneca Canada, Becton Dickinson Canada, Boehringer-Ingelheim Canada, Canadian Pharmacists Association, HLS Therapeutics, Janssen Pharmaceuticals, Lilly Canada, Merck Canada, MontMed Canada, New Brunswick Government - Department of Health - (Diabetes Task Force), Novo Nordisk, Sanofi Canada

Gail MacNeill

Gail MacNeill

Clinical Nurse Specialist and Nurse Consultant, Toronto, ON

Disclosures

Speakers Bureau/Honoraria: BD, Diabetes Canada, Lilly, Novo Nordisk
Facilitation: Diabetes Care Community

Sponsors

LEAD SUPPORTERS

 

 

VISIONARY SUPPORTER

 

CONTRIBUTOR SUPPORTER

 

Frequently Asked Questions

This year our conference goes virtual. Join us from the comfort of your own home!
Our virtual conference will take place from October 28th, 2020 to October 30th, 2020.
You will use the login credentials received in your registration confirmation email to enter the site. Once you login you will be taken to the virtual lobby and will be able to view welcome and instructional videos on how to navigate our virtual conference. You will receive a virtual conference bag which will include a detailed program, as well as additional diabetes related information from our sponsors.'

Much like an in-person conference you will be able to watch presentations in the virtual auditorium and participate in Q&A sessions. There is also an interactive tradeshow where you can visit a variety of diabetes related exhibits and ask questions of company representatives via chat box or arrange a private chat via audio or video options.
We have a great lineup of exhibitors at this year's conference:
Abbott
Ascensia Diabetes Care
AstraZeneca
Bayer
BD
Canadian Diabetes Prevention Program (CDPP)
Canola Eat Well
Canadian Society of Endocrinology & Metabolism (CSEM)
Dexcom
Diabetes Canada
Droplet by HTL-STREFA
Eli Lilly|Boehringer Ingelheim
Janssen
Lifestyle Hearing
Listerine®
Medtronic
Merck
Michener/UHN School of Continuing Education
Nestle Health Science
Novo Nordisk Canada Inc.
Omnipod
Recordati Rare Diseases Canada Inc.
Roche Diabetes Care
Sanofi Diabetes
Takeda Canada Inc.
Tandem Diabetes Care, Inc.
Ypsomed Diabetescare
Virtual events bring the experience of an in-person conference to your personal computer, so just like an in-person conference, you have the freedom to pick the sessions you attend. But many say that attending the event in its entirety will help you get the most out of the experience.
All diabetes and endocrinology professionals are welcome.
The Diabetes Canada/CSEM Professional Conference is Canada’s most highly anticipated diabetes-related conference.

It is an opportunity to:
  • Learn about significant advances in diabetes research, treatment, and care
  • Attend original research presentations that are accredited
  • Take part in information sharing with leading diabetes, endocrinology, and related field experts.
Absolutely. We are counting on you to invite others! Help us spread the word. You can simply share the link to this page and they can register at their convenience.
New in 2020, we will have:
  • Division by stream per day for Allied Health (October 28), Scientific (October 29), and CSEM (October 30)
  • Indigenous content integrated throughout
  • 45 min accredited sessions including live Q&A
  • Virtual Exhibit Hall
  • Virtual Poster Hall
  • Virtual Networking Opportunities
  • Cultural Safety Post-Conference Workshop
During the presentation, questions can be typed into the chat box at anytime, however the speaker will wait until the allotted Q & A period at the end of the presentation to answer questions from the audience.

Diabetes Action Canada Trainee Day

Diabetes Canada and Diabetes Action Canada are pleased to announce the Virtual Trainee Day: Shifting the Paradigm in Patient-Oriented Research: Are We There Yet? It will take place on Tuesday, October 27th, 2020 from 11:00 a.m. to 4:00 p.m. prior to the 2020 Diabetes Canada/Canadian Society of Endocrinology and Metabolism Professional Conference and Annual Meetings.

This is an excellent opportunity for trainees to learn about Patient-Oriented Research (POR) through patient partner stories, hone your grant writing skills, improve team building and learn about POR Decision tools

CSEM Residents’ Day Review

The Canadian Society of Endocrinology and Metabolism (CSEM) is excited to announce that the 2020 Residents' Day Review Course will be offered virtually on Tuesday, October 27, 2020 from 11:00 a.m. to 4:00 p.m., prior to the 2020 Diabetes Canada/Canadian Society of Endocrinology and Metabolism Professional Conference. Residents’ Day is FREE for CSEM Resident Members - Join CSEM. The day’s agenda will be posted on the CSEM website once confirmed.

Resident clinical vignettes and research project abstracts can be submitted here before September 7, 2020.

Residents’ Day consists of workshops and lectures on endocrinology topics led by experts in the field. It is specially designed to prepare you for the upcoming Royal College of Physicians and Surgeons of Canada certification exam in endocrinology.

The full conference registration fee includes access to all sessions, exhibits, posters, and sponsored events.

Registration Category Until Aug 12, 2020 Aug 13-Oct 21 Oct 22-30
DIABETES CANADA / CSEM PROFESSIONAL MEMBER
Member Full Conference Pass $100 $120 $145
One Day Member Conference Pass $75 $100 N/A
NON-MEMBER
Non-Member Full Conference Pass $200 $250 $300
One Day Non-Member Conference Pass $175 $225 N/A
MEMBER OPPORTUNITIES
Diabetes Canada Professional Membership* $75 $105 $105
Diabetes Canada Professional Membership (trainee, student) $0 $0 $0

All post-secondary students (e.g. Bachelors, Masters, PhD, post- doctoral or M.D.) enrolled at a college or university in a diabetes/health-care related field are eligible to become student members.

Student members enjoy the same benefits as regular members free of charge for up to two years.

Complete the application form and email it along with your proof of enrollment to professional.membership@diabetes.ca. All applicants must provide proof of full-time status that confirms the start and end dates of their program.

No, you do not need to download or install any software to participate in our conference. Nor do you need a webcam to take part. You only need to have access to the internet.
For any technical assistance, please contact us dcan2020@getvfairs.io OR visit our virtual Help Desk depicted in the internal lobby and a vFairs representative will be available to help you.

The vFairs platform includes the following accessibility features:

  • Ability to increase or decrease font size
  • Read-speaker
  • Colour contrast mode
Contact us via email at info@diabetes.ca or call 1-800-BANTING (226-8464) and our call centre staff will get back to you in 1-2 business days.